Vaxart

Historical price data

Vaxart's mission is to transform global health by developing oral recombinant pill vaccines that generate mucosal and systemic immunity. The company's core strategy leverages its proprietary delivery platform to create vaccines that are easier to administer, do not require cold-chain logistics, and could potentially reduce transmission of viruses. While still in clinical development, Vaxart aims to address significant unmet needs in infectious diseases with a more accessible and potentially more effective vaccine format.

Proprietary oral recombinant vaccine delivery platform using a non-replicating adenovirus vector to stimulate both mucosal and systemic immunity via a pill format.

Faces competition from vaccine giants (Sanofi, GSK) in influenza and emerging players in norovirus. Its primary differentiator is the oral pill format and focus on mucosal immunity, but it lacks the commercial scale and resources of its large-cap peers, making partnerships critical.